Elizabeth S. Stuart

Associate Professor
Director of Chlamydia Research & Vaccine Development

Phone: 413-545-6750
Fax: 413-545-1578
Email: esstuart@microbio.umass.edu
Mailing address

Ph.D.: Zoology, University of Chicago, 1967

Research Interests

  • Infection, immunity and pathogenesis with especial interest in processes used by chlamydial species for entry into host cells and replication
  • The generation, display and utility of recombinant vaccine components targeting viral or bacterial peptides
  • Vaccine components for use with chlamydia
 
 
A, D:
a-Chlamydia antibodies


B, E:
a-caveolin stain


C, F:
Merge of a-Chlamydia and a-caveolin stains.
 
Immunofluorescence stain showing colocalization of C.trachomatis serovar K, with the caveolae protein, caveolin-1.
J774A.1 (left) and McCoy cells (right) with Chlamydia trachomatis serovar K after 96 hours of infection. Large inclusions are seen fluorescing green in both pictures, however the inclusions in the J774A.1 cells are larger at the same time point. These and all cell types tested produce and release the chlamydial glycolipid exoatigen [GLXA].
GLXA associates with infected and uninfected cell membranes. The Glycolipid Exoantigen of Chlamydia is displayed on the surfaces of infected cells (A) when fixed with paraformaldehyde but is only seen associated with the inclusion when methanol fixed (B). GLXA also associates with the membranes of uninfected cells (C) when added before fixation compared with the untreated control (D).
Residual Cells from patient sample, fixed with paraformaldehyde and stained with anti-GLXA antibody. As is clear in this figure, in vivo infected cells produce and display GLXA.
Immunofluorescence stain showing colocalization of Chlamydiae species and strains, with the caveolae protein, caveolin-1.
 
 

Selected Publications

Cirino F, Webley WC, Croteau NL, Andrzejewski Jr. C. and Stuart ES. Detection of Chlamydia in the peripheral blood cells of normal donors using in vitro culture, immunofluorescence microscopy and flow cytometry techniques. BMC Infectious Diseases 2006; 6:23.

Webley WC, Salva PS, Andrzejewski C, Cirino F, West CA, Tilahun Y, Stuart ES. The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia. Am J Respir Crit Care Med. 2005 May 15;171(10):1083-8. Epub 2005 Feb 25.

Webley WC, Norkin LC, Stuart ES. Caveolin-2 associates with intracellular chlamydial inclusions independently of caveolin-1. BMC Infect Dis. 2004; Jul 22;4(1):23.

Stuart ES, Morshed F, Sremac M, DasSarma S. Cassette based presentation of SIV epitopes with recombinant gas vesicles from halophillic archeae. J Biotech. 2004; 114:225-237.

Webley WC, Vora GJ, Stuart ES. Cell surface display of the chlamydial glycolipid exoantigen [GLXA] demonstrated by antibody-dependent complement-mediated cytotoxicity. Curr Microbiol. 2004
Jul;49(1):13-2.

Vora GJ, Stuart ES. The chlamydial glycolipid exoantigen (GLXA) is broadly conserved and enhances pathogen infectivity. Curr Microbiol. 2003; 46(3):217-23.

Stuart ES, Webley WC, Norkin LN. Lipid rafts, Caveolae, Caveolin-1 and entry by Chlamydiae into host cells. Exp Cell Res. 2003; 287(1):67-78.

Stuart ES, Morshed F, Sremac M, DasSarma S. Antigen presentation using novel particulate organelles from halophilic archaea. J Biotechnol. 2001; 88(2):119-28.

Norkin LC, Wolfrom SA, Stuart ES. 2001. Association of caveolin with Chlamydia trachomatis inclusions at early and late stages of infection. Exp Cell Res. 2001; 266(2):229-38.

Whittum-Hudson JA, Rudy D, Gerard H, Vora G, Davis E, Haller PK, Prattis SM, Hudson AP, Saltzman WM, Stuart ES. The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis. Vaccine. 2001; 19(28-29):4061-71.

Whittum-Hudson JA, Vora G, Hudson A, Saltzman WM and Stuart ES. Protection against genital infection by the anti-idiotypic antibody (mAb2) mimic of chlamydial GLXA:TH1-dependent immunity? In Proceedings Fourth Meeting of the European Society for Chlamydia Research . ed. P Saikku, Universitas Helsiniki, Finland 2000 pp.429.

Vora G, and Stuart ES. The glycolipid exoantigen ,GLXA, enhances chlamydial infectivity in vitro and in the murine genital tract. In Proceedings Fourth Meeting of the European Society for Chlamydia Research . ed. P Saikku, Universitas Helsiniki, Finland 2000. pp.216.


PATENTS ISSUED or IN PROCESS

Australia Patent #2001251437 Stuart ES, Semprevivo, LH. Davis, E. Vora, GJ. Chlamydial Glycolipid Vaccines. Issued, 1.11.06.

US Patent #5,840,297 MacDonald AB, Stuart ES, Whittum-Hudson JA. Vaccine comprising anti-idiotypic antibody to Chlamydia GLXA and process. 1998.

US Patent #5,716,793 MacDonald AB, Stuart ES, An L-L, Whipkey MD. Method for diagnosing a patient for Chlamydia.1998.

US Patent #5,656,721 MacDonald AB, Whittum-Hudson JA, Saltzman WM. Oral vaccine comprising anti-idiotypic antibody to Chlamydia glycolipid exoantigen. 1997.

US Patent #5,824,309 DasSarma S, Morshed F, Stuart ES, Black S. Recombinant gas vesicles and uses. 1998.

Patent Application Submitted by UMass: Stuart ES “Detection, Imaging, and Depletion of Intracellular Pathogens” USSN# 60/659,964. 2005.

Patent Application Submitted by UMass: Stuart ES, Semprevivo, LH. "Detection and Quantification of Intracellular Pathogens” USSN # 60/563,087. 2004.

Patent Application submitted by UMass: Stuart, ES, Semprevivo, LH. . Davis, E. Vora, GJ. Chlamydial Glycolipid Vaccines USSN #09/827,490. 2001.  

Mailing Address

Elizabeth S.Stuart
Department of Microbiology
203 Morrill Science Center IVN
University of Massachusetts
639 North Pleasant Street
Amherst, MA 01003

 

Department of Microbiology
203 Morrill Science Center IVN
University of Massachusetts
639 North Pleasant Street
Amherst, MA 01003


413 545 2051  |  Fax 413 545 1578
© 2004 University of Massachusetts Amherst.
Site Policies.
This site designed by
Molecules in Motion
and maintained by the Department of Microbiology. Report site problems to webmaster.

 

UMass Amherst